University of Washington Health Sciences Research Studies Seeking Volunteers

70 item(s) returned.
To access detailed information about a study, click on the study #.

Specific Diseases or Conditions
Study #	Title
1809.00	A Feasibility Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients with Advanced AML or High Risk Myelodysplastic Syndrome
1992.00	A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.
2004.00	A Multi-Center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine
6106	A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck
20061195	A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors
2224.00	A Phase 1 / 2, Multi-Center, Open-Label, Dose-Escalation Study of Elotuzummab (Humanized anti-CS1 Monoclonal IgG1 antibody) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies
20060409	A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations.
6590	A Phase 2 Study of [18F]fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
20070773	A Phase I Study Evaluating a Second Generation Antisense Oligonucleotide (OGX-427) that Inhibits Heat Shock Protein 27 (Hsp 27)
20070527	A Phase I Open-Label Dose-Escalation, Safety and Pharmacokinetic Study of MDV3100 in Patients with Castration-Resistant Prostate Cancer
2267.00	A Phase I Study of GRN163L in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
2231.00	A Phase I Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
2230.00	A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation
20080865	A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 when Administered Orally to Patients with Prostate Cancer
6488	A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination with Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphaide plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer
6511	A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients with Locally Advanced, Resectable Pancreatic Adenocarcinoma
6803	A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
6137	A Phase II Study of Intermittent Gleevec® (Imatinib mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older with Advanced Non-Small Cell Lung Cancer
2161.00	A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression
20080081	A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer
6307	A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
1368.00	A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma
6168	A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) with Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Resistant Epithelial Ovarian Cancer
6583	A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
1860.00	A Phase III Randomized, Multicenter Study Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors
2245.00	A Phase III, Randomized, Open-Label, 3-Arm Study To Determine The Efficacy And Safety Of Lenalidomide (Revlimid®) Plus Low-Dose Dexamethasone When Given Until Progressive Disease Or For 18 Four-Week Cycles Versus The Combination Of Melphalan, Prednisone, And Thalidomide Given For 12 Six-Week Cycles In Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years Of Age Or Older Or Not Candidates For Stem Cell Transplantation
6346	A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness associated with Letrozole (Femara® )
2044.00	A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors with an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies
1981.00	A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation from HLA-Class I or Class II Mismatched, Unrelated Donors
6451	A Randomized Phase II Study of Docetaxel +/ - ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma
1938.00	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
6782	A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease
2345.00	An Open-label, Multicenter, Randomized Phase II Study to Investigate the Safety, Tolerability, and Efficacy of RO5072759 Versus Rituximab in Patients with Relapsed CD20+ Indolent B-cell Non-Hodgkin’s Lymphoma
1959.00	Campath® (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies: a Multicenter Trial
33567	Canary Prostate Active Surveillance Study
6817	Combination Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma (PLD-BCD)
2272.00	Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
6562	Dose Escalation Study of Clofarabine in Combination with Cytarabine (ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients
6228	Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer
6140	Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients
6566	FDG-PET Based Chemotherapy Selection for Metastatic Non-Small Cell Lung Cancer
2051.00	Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia
2186.00	Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After Transplantation
2007.00	Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®
1227.00	Induction of Mixed Hematopoietic Chimerism in Patients with Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow from an HLA-Matched Related Donor and Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil
973730AC05	Intermittent Hormone Therapy in Men with Localized Prostate Cancer Who Have Biochemical Relapse After External Beam Irradiation or Radical Prostatectomy
2056.00	Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders – A Multi-Center Trial
6379	Men's Shift Worker Study
2128.00	Multi-center, Open label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood Transplantation in Pediatric Patients with High Risk Leukemia and Myelodysplasia
6408	Multicentre, Double-Blind Study Comparing 0.5mg Dutasteride vs. Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer
1840.00	Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial
2064.00	Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study
1667.00	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation
2243.00	Phase 1b Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma
6621	Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
6600	Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined with Paclitaxel and Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin
6658	Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer
6707	Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
6166	Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients with Locally Advanced or Stage IV HER2 Positive Breast Cancer
6857	Phase II Study of Neoadjuvant IMC-A12 Combined with Androgen Deprivation Prior to Prostatectomy
6578	Phase II Study of Topical Imiquimod and Weekly Abraxane® for the Treatment of Breast Cancer Cutaneous Metastases
6308	Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer
6229	Positron Emission Tomography (PET) for Evaluation of Acetate Metabolism in Prostate Cancer
6129	Positron Emission Tomography Imaging of Bone in Patients with Metastatic Prostate Cancer – A Pilot Study Evaluating Treatment Response
20062200	Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-Controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy
30824	SCORE! - Assessment of Mood, Information Processing, and Quality of Life following Prostate Cancer
30824	SCORE! - Assessment of Mood, Information Processing, and Quality of Life in ADT
2239.00	Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen
2275.00	Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen
2010.00	Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen